DeltaDot Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DeltaDot Ltd. - overview
Established
2000
Location
London, -, UK
Primary Industry
Biotechnology
About
DeltaDot Ltd. is a biotechnology company specializing in High Performance Capillary Electrophoresis (HPCE) instruments designed for advanced analytical applications in life sciences. Founded in 2000, DeltaDot Ltd. is based in London, UK, and specializes in high-performance analytical instruments.
The company has undergone strategic shifts, including a focus on veterinary diagnostics. In October 2007, DeltaDot raised GBP 3 million in a Series D funding round led by FPE Capital, with participation from Company Guides, NPI Ventures, and others, contributing to a total amount raised of GBP 3 million. DeltaDot Ltd. specializes in High Performance Capillary Electrophoresis (HPCE) instruments, utilizing proprietary technologies to enhance analytical capabilities within the life sciences sector.
Their flagship product, the iohexol assay, accurately measures glomerular filtration rate (GFR), primarily benefiting veterinary diagnostics. DeltaDot serves research institutions, pharmaceutical companies, and bio-pharmaceutical manufacturers across North America, Europe, and Asia. In the most recent fiscal year of 2016, DeltaDot Ltd. reported a revenue of GBP 355,913 with an EBITDA of GBP -281,648.
8. The company operates on a B2B model, generating revenue through the sale of HPCE instruments and related analytical services. DeltaDot Ltd. aims to leverage the GBP 3 million raised in its Series D funding round to enhance product development and expand into new markets.
Plans include designing upcoming products tailored for the veterinary diagnostics sector, with a targeted launch in late 2024. The company is specifically looking to increase its footprint in the North American and Asian markets by 2025, aiming to foster long-term partnerships through scientific collaborations.
Current Investors
FPE Capital, Company Guides, Touchstone Innovations
Primary Industry
Biotechnology
Sub Industries
Bioinformatics
Website
www.deltadot.com
Company Stage
Series D
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.